FICCI recommends PLI-like scheme to ramp-up vaccine production

The chamber in its press release highlighted that India intends to vaccinate priority population of 30 crore by August 2021.

37

New Delhi: Industry body FICCI on Tuesday recommended the government to provide Production Linked Incentive-type scheme in order to ramp up C-19 vaccine production as cases continue to see a rapid surge in India.

The chamber in its press release highlighted that India intends to vaccinate priority population of 30 crore by August 2021.


To read more articles on FICCI, click here


Given that 10.85 crore people have received at least 1st dose of C-19 vaccination and going with the current rate of 30 lakh vaccinations per day, we would need more than 38 crore doses (of two dose vaccines) to fully vaccinate this priority group. According to reports, Indian government has 2.04 crore doses in pipeline for next few days.

Medicine Vaccine Injection
Picture: Pixabay

Expressing concerns over shortage of C-19 vaccines in various states of the country, FICCI warned, “With the current strategy and vaccination rate, we would be missing vaccinating our super-spreaders of the age group 18-45 years, who also form the majority of our workforce needed for sustaining economic activities.


Also read:

Drug alert: 3.52% samples declared NSQ: NIB

Russia’s Sputnik V gets Emergency Use authorisation nod in India

Biocon Pharma gets GMP compliance certificate from UK

IPC releases draft chapter on “Approach to alternative rapid microbiological methods”


Furthermore, since the length of immunity provided by the vaccines is yet not known, we would need to factor in repeat vaccination and maintain the momentum of manufacturing for at least next couple of years.”

“The vaccines that are proven and successful in other markets should be encouraged to be brought into India at the earliest, in order to maintain our supply chains. This should be considered for import and sale of international vaccines as well as initiate manufacturing of such vaccines in the country.


To read more articles on vaccine, click here


Given that most of these vaccines have extensive dossier and data on their safety and efficacy for large populations, including for Indians living abroad, we should waive off the need for Indian clinical trial data,” the industry body further added.

FICCI stated that since the government has capped cost of vaccines, it should provide appropriate incentives to manufacturers in a bid to encourage them to substantially augment their production capacities. It recommended financing the vaccine companies by offering PLI-type Scheme, immediate and sufficient grants and subsidies provision through Centre’s C Funds.


Enter your email address:

Delivered by FeedBurner

Latest updates

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading